ImpediMed Hits Record A$6.3M Contract Value, Secures Additional $5M Funding
ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.
- US unit sales doubled to 44 in Q4 FY25
- Record quarterly total contract value of A$6.3 million
- Secured additional US$5 million tranche from SWK Funding LLC
- Key 9-unit contract with Legacy Health for lymphoedema prevention
- Positive outlook with strong sales pipeline for FY26
Strong Sales Momentum in the US Market
ImpediMed Limited (ASX – IPD) has reported a significant surge in its US sales during the fourth quarter of fiscal year 2025, doubling unit sales from 22 in the previous quarter to 44. This growth not only surpasses the same quarter last year by 91% but also drives the company’s total contract value (TCV) to a record A$6.3 million, up 29% from Q3 FY25. This milestone reflects the successful execution of initiatives under the company’s new leadership and growing market acceptance of its SOZO Digital Health Platform.
Capital Growth Facility Drawdown
As a direct consequence of meeting its FY25 sales targets, ImpediMed has elected to draw down the second tranche of US$5 million from its previously announced US$15 million capital growth facility with SWK Funding LLC. This move extends the interest-only period on the facility from 24 to 36 months, providing the company with enhanced financial flexibility to support its growth and commercialisation strategies while limiting equity dilution.
Strategic Contract Win with Legacy Health
A highlight of the quarter was a 9-unit contract with Legacy Health, a prominent six-hospital system in the Portland, Oregon and Vancouver, Washington areas. Legacy Health’s adoption of the SOZO platform as part of its lymphoedema prevention program underscores the clinical relevance and growing demand for ImpediMed’s technology. The program aligns with Legacy Health’s commitment to improving cancer survivorship outcomes by enabling early detection and proactive management of lymphoedema, a condition that significantly impacts quality of life for many cancer survivors.
Outlook and Growth Pipeline
ImpediMed’s management remains optimistic about sustaining and building on this momentum into FY26. The company has a robust sales pipeline and anticipates continued conversion of leads into sales, supported by ongoing internal initiatives and favorable reimbursement guidelines. CEO Dr Parmjot Bains emphasized the depth and quality of new accounts and partnerships, signaling confidence in the company’s trajectory towards profitability.
Positioning for Long-Term Value Creation
Chair Christine Emmanuel-Donnelly highlighted that the capital facility drawdown reflects the board’s confidence in the company’s foundation and growth prospects. By securing additional funding without diluting equity, ImpediMed is better positioned to capitalise on significant market opportunities in the US and beyond. The company’s FDA-cleared SOZO platform, combined with its SaaS subscription model, offers a scalable pathway to capture the expanding cancer-related lymphoedema market.
Bottom Line?
ImpediMed’s Q4 surge and funding boost set the stage for accelerated growth, but execution risks remain as the pipeline matures.
Questions in the middle?
- How quickly will the sales pipeline convert into sustained revenue growth in FY26?
- What impact will the additional capital have on the company’s path to profitability?
- Can ImpediMed expand its footprint beyond the US market with current resources?
